6533b85efe1ef96bd12bf323
RESEARCH PRODUCT
Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q
Andreas FaldumThorsten SimonBarbara HeroFrank BertholdRüdiger Spitzsubject
AdultRiskOncologyCancer Researchmedicine.medical_specialtyPathologyMultivariate analysisAdolescentBiologyN-Myc Proto-Oncogene ProteinDisease-Free SurvivalNeuroblastomaNeuroblastomaInternal medicinemedicineHumansStage (cooking)ChildRetrospective StudiesChromosome AberrationsOncogene ProteinsN-Myc Proto-Oncogene ProteinChromosomes Human Pair 11Mortality rateInfant NewbornInfantNuclear ProteinsChromosomeRetrospective cohort studySingle copymedicine.diseaseOncologyChromosomes Human Pair 1Child Preschooldescription
In localized neuroblastoma, the identification of patients requiring intensive treatment is still difficult. We retrospectively analyzed data of 280 single copy MYCN stage 2 and 3 neuroblastoma patients with gross residual tumor after initial surgery. The 3-year-event free survival of the total group was 83+/-2%, and 3-year-overall survival was 92+/-2%. Patients < or=1.5 years had a better outcome than older children. Deletions/imbalances of chromosome 1p were found in 9/90 patients and were associated with a higher event rate but not with a higher death rate. Aberrations of chromosome 11q in 14/91 patients were correlated with a higher event and death rate. Multivariate analysis identified 1p aberrations as important for event free survival and 11q aberrations for overall survival.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2006-06-01 | Cancer Letters |